Short- and Long-Term COX-2 Inhibition Reverses Endothelial Dysfunction in Patients With Hypertension
Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M, Maxwell C, Palmisano J, Keaney JF, Morrow JD, Vita JA. Short- and Long-Term COX-2 Inhibition Reverses Endothelial Dysfunction in Patients With Hypertension. Hypertension 2003, 42: 310-315. PMID: 12874094, DOI: 10.1161/01.hyp.0000084603.93510.28.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalysis of VarianceBlood PressureBrachial ArteryCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDouble-Blind MethodEndothelium, VascularFemaleHumansHypertensionIsoenzymesMaleMembrane ProteinsMiddle AgedNitroglycerinProstaglandin-Endoperoxide SynthasesProstaglandinsPyrazolesSulfonamidesTime FactorsVasodilationConceptsFlow-mediated dilationEndothelial dysfunctionUrinary concentrationsCelecoxib treatmentBrachial artery flow-mediated dilationArtery flow-mediated dilationEndothelium-derived nitric oxideSelective cyclooxygenase-2 inhibitor celecoxibBrachial artery vasodilator functionBaseline arterial diameterCyclooxygenase-2 productsCyclooxygenase-2 inhibitor celecoxibDouble-blind studyNitroglycerin-mediated dilationWeeks of treatmentCyclooxygenase-2 activityCyclooxygenase-2 inhibitionCyclooxygenase-2 inhibitorProstacyclin metaboliteVasoconstrictor prostanoidsVasodilator functionHypertensive patientsFirst doseEndothelial functionPlacebo treatment